An interventional study of Bright Light Therapy and Blue Light Blocking Glasses in Depression, Unipolar and Depression, Bipolar, sponsored by Universiteit Leiden. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Universiteit Leiden · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Depressive Disorder with a site in Netherlands — 7 open to participants now, 9 under way, none of them phase 3. Depressive Disorder · Netherlands.
Among the 18 studies in Depressive Disorder with a site in Netherlands, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 15th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →7 of the 18 studies in Depressive Disorder with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Arkin · Sites in Netherlands
Ages 18–65
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
UMC Utrecht · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 231 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 151 across the 16 interventional studies, 216 across the 2 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
Universiteit Leiden is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Universiteit Leiden has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07022184Radboud University Medical CenterLifestyle Intervention for Symptoms of Depression wIth App Support in General Practice | 2026-11 |
| NCT05640089Maastricht University Medical CenterFMRI-neurofeedback in Depression | 2027-04-30 |
| NCT07950800ArkinFrom There Towards Now; Intervention for Jewish and Indonesian Post-war Generations | 2027-08-01 |
| NCT05551468Ggz Oost BrabantStayFine: Personalised Relapse Prevention of Anxiety and Mood Disorders in Youths | 2027-11-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Depressive Disorder with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response.
This clinical trial has three main goals:
The specific objectives are as follows:
In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups:
The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard Care - BLT in the home environment
Procedure: Bright Light Therapy
BLT will be administered in a specialized cafe, under the supervision of clinical staff, promoting lifestyle changes and social interaction.
Procedure: Bright Light Therapy
Treatment will be identical to the second arm but now complemented with the use of blue-light blocking glasses in the evening and the adoption of personalized BLT timing based on sleep-wake patterns
Procedure: Bright Light Therapy · Device: Blue Light Blocking Glasses
In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
Clinical Improvement
Difference between pre- and post-treatment assessment of the Montgomery Asberg Depression Rating Scale \[MADRS\]
Time frame: 2-5 weeks
Subjective change in depressive symptom severity
Change in score on the Quick Inventory of Depressive Symptoms, Self Report (QIDS-SR)
Time frame: from baseline until follow-up, approximately 4 months
Remission rates, self assessed and clinician rated
percentage of patients that after treatment have a score of \<6 on the MADRS or QIDS-SR
Time frame: 2-5 weeks for clinician rated. Up until 4 months after start treatment for self-assessed
Response Rates, self assessed and clinician rated
percentage of patients hat after treatment have at least 50% reduction in depressive symptom, measured using MADRS and QIDS-SR
Time frame: 2-5 weeks for clinician rated, Up until 4 months after start treatment for self-assessed
Time to remission
The time it takes to achieve remission, if remission is achieved. Measured with QIDS-SR
Time frame: one, two or three weeks
Circadian phase
Changes in circadian phase will be compared between groups as assessed using the DLMO (calculated from the melatonin assessments) and complemented with actigraphy data (using sleep onset timing, least active 5h period and most active 10h period)
Time frame: 2-5 weeks
Circadian amplitude
Changes in the circadian amplitude will be compared between groups. The amplitude can be estimated from actigraphy data by the difference in activity between the most active 10h and the least active 5h normalized for total activity.
Time frame: 2-5 weeks
Circadian Periodicity
Changes in circadian periodicity will be compared between groups. Circadian periodicity is a period of an oscillating rhythm assessed via periodogram analysis of the activity time-course of actigraphy data. The deviation between the maximum period of the periodogram and the normal daily period of 24h reflects pattern variability in normal entrainment conditions.
Time frame: 2-5 weeks
Inter-daily stability
Constancy of the 24-h rhythmic pattern over days
Time frame: 2-5 weeks
Intra-daily variability
rhythm fragmentation
Time frame: 2-5 weeks
Chronotype
Chronotype changes as assessed with the Morningness-Eveningness Questionnaire(MEQ) and the Ultra-Short Version of the Munich Chronotype Questionnaire (µMCTQ)
Time frame: 1-3 months
Sleep-Wake Pattern
Actigraphy and questions from The Consensus Sleep Diary will provide sleep onset time, sleep offset time, midsleep time, total sleep time, sleep onset latency, number of awakenings and time awake during the night.
Time frame: 2-5 weeks
Sleep Quality
Fragmentation index (degree of movement during the night), sleep efficiency (total sleep time expressed as a percentage of time in bed) will be calculated using actigraphy data. The Pittsburgh Sleep Quality Index (PSQI) will provide a subjective measure of sleep quality.
Time frame: 2-5 weeks for actigraphy, up until 4 months after the start of treatment for subjective sleep quality
Severity of Insomnia Symptoms
Severity of Insomnia Symptoms as assessed with the Insomnia Severity Index
Time frame: up until 4 months after the starts of treatment
Momentary Positive/Negative Affect
The EMA will consist of items from the Positive and Negative Affect Scale (PANAS) to assess momentary positive and negative affect
Time frame: 2-5 weeks
Momentary Vitality
The EMA will contain 4 items concerning energy levels and alertness adapted from Activation-Deactivation Adjective Checklist
Time frame: 2-5 weeks
Gray matter structure
Properties of gray matter structure (thickness, volume, surface area and gyrification) of the whole brain as well as of the white matter structure (integrity of main white matter fiber tracts-fractional anisotropy (FA))
Time frame: 2-5 weeks
Functional connectivity of the brain
Functional connectivity of the brain under resting state condition - the communication of specific brain regions which work as a network without conducting a specific task
Time frame: 2-5 weeks
Personal daily light exposure
the percentage of time exposed to light above the threshold of 300 lux will be calculated from light sensor data as well as the mean timing thereof (MLiT100). Additional parameter might be extracted from the light exposure data based on state of the art procedures.
Time frame: 2-5 weeks
Treatment expectations
Treatment expectations will be assessed using the Credibility/expectancy Questionnaire
Time frame: baseline
Light Induced Melatonin suppression
Light Induced Melatonin suppression as assessed using the salivary melatonin assessments will give insight into light sensitivity of the participants.
Time frame: Baseline
Treatment Adherence
Treatment adherence will be assessed subjectively using an item in the EMA and objectively using light logger devices.
Time frame: 1-3 weeks
Side Effects
Side effects will be monitored with a questionnaire based on the Toronto Side Effects Questionnaire
Time frame: 1-3 weeks
Plan to share: Yes — All data underlying a publication can be shared upon request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available after publication of the analyses
Access criteria: Access may be granted to researchers who intend to conduct secondary analyses or meta-analyses using individual participant data. Additionally, researchers with a valid scientific research question or hypothesis that aligns with the objectives of the original study may be considered for IPD access.
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Sep 2026, 31 months after the start.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 31 months is close to that.
Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universiteit Leiden